<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876732</url>
  </required_header>
  <id_info>
    <org_study_id>09-024</org_study_id>
    <nct_id>NCT01876732</nct_id>
    <nct_alias>NCT01360983</nct_alias>
  </id_info>
  <brief_title>Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients</brief_title>
  <official_title>Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Staten Island University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin B12 has several important functions in the body, two of which are production of red
      blood cells and the maintenance of a healthy nervous system. When vitamin B12 is deficient,
      abnormal red blood cells form. These cells are called megaloblasts. The end result is a
      decreased number of red blood cells; a condition called anemia. Some symptoms of anemia
      include fatigue, weakness, shortness of breath, and pallor. Vitamin B12 is also important in
      maintaining a healthy nervous system. Nerves are surrounded by an insulating material that
      helps them conduct impulses. Patients with low B12 levels who receive this vitamin in
      injection form, state that there quality of life is better. Anemia in Hemodialysis patients
      is treated with Epogen, a synthetic material which helps your body make blood cells. The
      investigators believe that if you have a low vitamin B12 level in your blood and the
      investigators give you the vitamin during dialysis your requirement for epogen will be lower
      and you will be able to produce blood cells better. When evaluating for Vitamin B12
      deficiency a special test is needed called methylmalonic acid level (MMA). This is a blood
      test that will be performed and when this level is high and your vitamin B12 level is in the
      low normal range the investigators can make a diagnosis of vitamin B12 deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND: Vitamin B12 deficiency may have deleterious effects on end stage renal disease
      (ESRD) patients on maintenance hemodialysis, and may increase erythropoietin stimulating
      agent (ESA) resistance, yet little is known about its prevalence in this population.

      METHODS: Serum vitamin B12 and methylmalonic acid (MMA) levels were drawn from ESRD patients
      prior to hemodialysis. All patients with MMA levels greater than 800 nmol/L had peripheral
      smears evaluated for B12 deficiency. Those with confirmatory smears were considered to be
      deficient and received intramuscular vitamin B12 injections for 4 months. Post-treatment MMA
      levels and smears were obtained. Erythropoietin dosages were monitored throughout the
      treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Amount of Epogen Required</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>The effects of Vitamin B12 supplementation on erythropoitin alpha (Epogen) requirements in HD patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life</measure>
    <time_frame>3 month</time_frame>
    <description>The scoring procedure for the KDQOL-36 (Kidney Disease Quality of Life Instrument adopted for quality of life assessment of patients with kidney disease),first transforms the raw precoded numeric values of items to a 0-100 possible range with higher transformed scores reflecting a better quality of life. Each item is put on a 0 to100 range so that the lowest and highest possible scores are set at 0 and100, respectively. The results entered in the outcome data is the mean absolute difference between the mean pre-test score and the mean post-test score.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Vitamin B12 Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin B12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B12</intervention_name>
    <description>Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.</description>
    <arm_group_label>Vitamin B12</arm_group_label>
    <other_name>Cyanocobalamin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  · Patients on Hemodialysis for at least 6 months

               -  Patients on stable dose of epogen and iron supplementation for at least 1 month
                  prior to B12 and MMA assay.

        Exclusion Criteria:

          -  · On B12 treatment

               -  Hematological Cancer

               -  Methotrexate use

               -  Alcohol use greater then 2 drinks per day

               -  Vegetarian Diet

               -  Gastric Surgery

               -  Inflammatory Bowel Disease

               -  Pernicious Anemia

               -  Recent transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne El-Sayegh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SIUH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Island Rehab</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>June 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2013</study_first_posted>
  <results_first_submitted>February 6, 2014</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 8, 2014</results_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Suzanne El-Sayegh</investigator_full_name>
    <investigator_title>Nephrology Attending, Assoc. Chair of Medicine</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>viatmin B12 deficiency</keyword>
  <keyword>Epogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin B12</title>
          <description>Those with an methylmalonic acid (MMA) over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
Vitamin B 12: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>MMA was not over 800mg/dL</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin B12</title>
          <description>Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>From a single center dialysis unit, patients 18-80 on hemodialysis at least 6 months and taking Epogen were screened for serum Vitamin B12 levels and plasma MMA. Those with an MMA level greater than 800mmol/L had smears of their peripheral blood examined to assess for characteristic findings that are consistent with vitamin B12 deficiency.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.43" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Amount of Epogen Required</title>
        <description>The effects of Vitamin B12 supplementation on erythropoitin alpha (Epogen) requirements in HD patients</description>
        <time_frame>Baseline and 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
Vitamin B12: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first HD session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a KDQOL-36 prior to therapy and again post treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Amount of Epogen Required</title>
          <description>The effects of Vitamin B12 supplementation on erythropoitin alpha (Epogen) requirements in HD patients</description>
          <units>unit/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16,572" spread="41,902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life</title>
        <description>The scoring procedure for the KDQOL-36 (Kidney Disease Quality of Life Instrument adopted for quality of life assessment of patients with kidney disease),first transforms the raw precoded numeric values of items to a 0-100 possible range with higher transformed scores reflecting a better quality of life. Each item is put on a 0 to100 range so that the lowest and highest possible scores are set at 0 and100, respectively. The results entered in the outcome data is the mean absolute difference between the mean pre-test score and the mean post-test score.</description>
        <time_frame>3 month</time_frame>
        <population>Subjects were asked to complete a KDQOL-36 (Kidney Disease Quality of Life Instrument adopted for quality of life assessment of patients with kidney disease), once prior to therapy, and then again at the end of 3 months when therapy (when therapy is completed), was completed. Pre and post results will be compared.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin B12</title>
            <description>Those with an methylmalonic acid (MMA) over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
Vitamin B 12: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life</title>
          <description>The scoring procedure for the KDQOL-36 (Kidney Disease Quality of Life Instrument adopted for quality of life assessment of patients with kidney disease),first transforms the raw precoded numeric values of items to a 0-100 possible range with higher transformed scores reflecting a better quality of life. Each item is put on a 0 to100 range so that the lowest and highest possible scores are set at 0 and100, respectively. The results entered in the outcome data is the mean absolute difference between the mean pre-test score and the mean post-test score.</description>
          <population>Subjects were asked to complete a KDQOL-36 (Kidney Disease Quality of Life Instrument adopted for quality of life assessment of patients with kidney disease), once prior to therapy, and then again at the end of 3 months when therapy (when therapy is completed), was completed. Pre and post results will be compared.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Social Function (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" spread="29.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Function (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.50" spread="24.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom/problem list (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.62" spread="18.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom/problem list (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.69" spread="19.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effects of kidney disease (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.29" spread="26.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effects of kidney disease (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.58" spread="26.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden of kidney disease pre-test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.75" spread="31.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden of kidney disease (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="29.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.67" spread="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="30.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive function (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.11" spread="28.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive function (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.44" spread="29.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of social interaction (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.67" spread="26.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of social interaction (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.11" spread="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual function (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.50" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual function (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.00" spread="23.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.33" spread="24.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social support (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78" spread="32.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social support (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.78" spread="29.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dialysis staff encouragement (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" spread="15.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dialysis staff encouragement (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.50" spread="16.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall health (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.67" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall health (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="27.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.11" spread="22.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.22" spread="17.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.33" spread="30.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.00" spread="27.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.33" spread="38.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00" spread="40.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.83" spread="36.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.83" spread="33.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.92" spread="17.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.33" spread="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.00" spread="21.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.00" spread="20.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-emotional (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" spread="44.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-emotional (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.56" spread="46.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatigue (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.33" spread="27.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatigue (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" spread="17.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 physical composite (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.06" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 physical composite (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.12" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 mental composite (pre-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.88" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 mental composite (post-test)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.83" spread="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social function (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.83" spread="19.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom/problem list (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.13" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Effects of kidney disease (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="9.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burden of kidney disease (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work status (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.00" spread="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cognitive function (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="28.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of social interaction (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="20.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social support (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="39.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dialysis staff encouragement (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="21.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall health (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="19.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patient satisfaction (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.89" spread="15.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="17.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.67" spread="43.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="36.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emotional well-being (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.00" spread="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-emotional (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" spread="46.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy/fatigue (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="21.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 physical composite (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-12 mental composite (pre to post change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="9.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <p_value_desc>P- value for &quot;social function&quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.688</p_value>
            <p_value_desc>P- value of &quot; symptom/problem list &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.772</p_value>
            <p_value_desc>P- value of &quot; effects of kidney disease &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.301</p_value>
            <p_value_desc>P-value of &quot; burden of kidney disease &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.250</p_value>
            <p_value_desc>P-value of &quot; work status &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.895</p_value>
            <p_value_desc>P-value of &quot; cognitive function &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.281</p_value>
            <p_value_desc>P-value of &quot; quality of social interaction &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>P-value of &quot; sleep &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>P-value of &quot; social support &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.943</p_value>
            <p_value_desc>P-value of &quot; dialysis staff encouragement &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <p_value_desc>P-value of &quot; overall health &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.090</p_value>
            <p_value_desc>P-value of &quot; patient satisfaction &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <p_value_desc>P-value of &quot; physical functioning &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.438</p_value>
            <p_value_desc>P-value of &quot; role-physical &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.424</p_value>
            <p_value_desc>P-value of &quot; pain &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.169</p_value>
            <p_value_desc>P-value of &quot; general health &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.858</p_value>
            <p_value_desc>P-value of &quot; emotional well-being &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.156</p_value>
            <p_value_desc>P-value of &quot; role-emotional &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>P-value of &quot; energy/fatigue &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.583</p_value>
            <p_value_desc>P-value of &quot; SF-12 physical composite &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.358</p_value>
            <p_value_desc>p-value of &quot; SF-12 mental composite &quot;</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin B12</title>
          <description>Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
Vitamin B12: Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first HD session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a KDQOL-36 prior to therapy and again post treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were too few patients with MMA levels over 800 to determine sensitivity.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Suzanne El-Sayegh</name_or_title>
      <organization>Staten Island University Hospital</organization>
      <phone>718-226-6158</phone>
      <email>uviola@siuh.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

